Responses
Clinical/translational cancer immunotherapy
Original research
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
Compose a Response to This Article
Other responses
No responses have been published for this article.